Is Reliance on Mitochondrial Respiration a “Chink in the Armor” of Therapy-Resistant Cancer?
Cet article passe en revue les travaux récents suggérant l'intérêt d'inhibiteurs de la respiration mitochondriale pour surmonter une résistance thérapeutique dans divers cancers, notamment les lymphomes et les mélanomes
A series of recent reports has suggested PGC1α-driven upregulation of mitochondrial oxidative phosphorylation as a selective vulnerability of drug-resistant cancers. Accordingly, chemical inhibitors of respiration led to selective eradication of such cancer cells due to their preferential sensitivity to mitochondrial production of reactive oxygen species. These insights create a timely opportunity for a biomarker guided application of already existing and newly emerging mitochondrial inhibitors in recurrent drug-resistant cancer, including lymphomas, melanomas, and other malignant diseases marked by increased mitochondrial respiration.